Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial
Authors' conclusion
Based on the mediation analysis, treating both sleep-disordered breathing and obesity is likely required to optimize the treatment effect on cardiometabolic benefits for patients with moderate-to-severe OSA and obesity.
Study context
- Population
- Participants with moderate-to-severe obstructive sleep apnea (OSA) and obesity
- Comparison
- Tirzepatide vs placebo
- Primary endpoint
- Cardiometabolic risk measures (prespecified analysis)
- Follow-up
- 52 weeks
Methodological detailsprespecified analysis, post hoc analyses, two 52-week studies (study 1 and study 2), double-blind, placebo-controlled, phase 3, mediation analysis
- Prespecified analysis
- Post hoc analyses
- Two 52-week studies (study 1 and study 2)
- Double-blind
- Placebo-controlled
- Phase 3
- Mediation analysis
Primary result
As reported in the abstract
Cardiometabolic risk factors
- In both study 1 and study 2, tirzepatide was associated with greater alleviation of cardiometabolic risk factors than placebo
Further findings
Mediation analysis (post hoc)
- Independent mediation effect of changes in OSA metrics on hsCRP, HOMA-IR and TG
- Combined changes in weight and OSA metrics, and weight alone, had a significant mediation effect on systolic BP
- No significant mediation effect of weight or OSA metrics on diastolic BP
- Post hoc
Original publication
Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial. Nat Med. Published 15 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →